Hot Features
Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an innovative immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. Toripalimab is being evaluated in pivotal clinical trials for the treatment of cancers of the... Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an innovative immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. Toripalimab is being evaluated in pivotal clinical trials for the treatment of cancers of the lung, breast, liver, skin, kidney, stomach, esophagus, and bladder. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company is also developing CHS-305, a biosimilar of Avastin. The company generates revenue primarily from the United States. Mehr anzeigen
REDWOOD CITY, Calif., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that senior management will present at the 43rd Annual J.P. Morgan...
- Randomized Phase 2 study initiated evaluating the combination of casdozokitug, toripalimab and bevacizumab in patients with liver cancer - REDWOOD CITY, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.11 | -7.33333333333 | 1.5 | 1.6 | 1.38 | 1548318 | 1.4513891 | CS |
| 4 | -0.05 | -3.47222222222 | 1.44 | 1.7699 | 1.35 | 1990282 | 1.49948067 | CS |
| 12 | 0.59 | 73.75 | 0.8 | 2.43 | 0.6603 | 5277670 | 1.43058878 | CS |
| 26 | -0.39 | -21.9101123596 | 1.78 | 2.43 | 0.6603 | 3559126 | 1.34824017 | CS |
| 52 | -0.93 | -40.0862068966 | 2.32 | 2.97 | 0.6603 | 3042285 | 1.70131723 | CS |
| 156 | -12.68 | -90.1208244492 | 14.07 | 14.11 | 0.6603 | 2524370 | 3.77796308 | CS |
| 260 | -18.57 | -93.0360721443 | 19.96 | 23.03 | 0.6603 | 1918277 | 6.60333409 | CS |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
